- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03405285
Connected Catheter Clinical Feasibility Study( CFS)
September 24, 2018 updated by: Spinal Singularity
Clinical Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
The objective of this study is to evaluate the safety and essential performance of the Connected Catheter System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting, and during and extended period (up to 29 days) of home use.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The Connected Catheter (C2P) is a replaceable urinary prosthesis that is intended for use in male patients 18 years of age or older who have impaired bladder emptying due to neurogenic lower urinary tract dysfunction, and who are capable of operating the device in accordance with the provided instructions for use, or who have trained caregivers capable of doing the same.
The device must be replaced every 29 days
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Downey, California, United States, 90241
- West Coast Urology, 11411 Brookshire Avenue, Suite 508
-
Murrieta, California, United States, 92562
- Tri Valley Urology, 25495 Medical Center Dr., Suite 204
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males age ≥ 18 with clinical diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)
- Must be clinically suitable and capable of safely managing bladder using an intermittent voiding strategy Must have stable urinary management history with clean intermittent catheterization: no significant changes in bladder management regimen within past 12 months
OR:
Must have urodynamic profile suitable for CIC, as assessed via urodynamics study within past 12 months (including bladder capacity > 200mL without uninhibited bladder contractions)
- Subject's lower urinary tract anatomy (lengths of proximal and distal urethral must fall within the ranges serviceable by the Connected Catheter device, as specified in the investigational device instructions for use.
- For cases of NLUTD due to spinal cord injury, the subject must be in medically stable condition (i.e. post-spinal shock phase)
Exclusion Criteria:
- Active symptomatic urinary tract infection, as defined in this protocol (subjects may receive the CoCath Device after UTI has been treated)
- Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days)
- Significant risk profile or recent history of clinically significant autonomic dysreflexia (e.g. History of hospitalization due to AD within past 12 months)
- Significant intermittent urinary incontinence (between catheterizations)
- Uninhibited bladder contractions and/or vesico-ureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. botox injections)
- Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy, urine analysis, and blood labs)
- Urinary tract inflammation or neoplasm
- Urinary fistula
- Bladder diverticulum (outpouching) > 5cm in size
- Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months)
- Impaired kidney function or renal failure (assessed via blood creatinine levels > 2 mg/dL)
- Active gross hematuria
- Active urethritis
- Bladder stones
- Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device
- Individuals allergic or otherwise unable to take oral antibiotics
- Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the CoCath System
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Connected Catheter Feasibility Study
Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
|
The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g.
due to spinal cord injury).
The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from genito-urinary injury/trauma
Time Frame: 29 Days
|
Improved bladder management without injury or trauma to genito-urinary tract
|
29 Days
|
|
Successful Acute Performance- I
Time Frame: On the day of Connected Catheter Insertion
|
To evaluate successful retention of Connected Catheter and Void
|
On the day of Connected Catheter Insertion
|
|
Successful Acute Performance -II
Time Frame: On the day of Connected Catheter Insertion
|
To evaluate successful bladder voiding with Connected Catheter
|
On the day of Connected Catheter Insertion
|
|
Successful Acute Performance- III
Time Frame: On the day of Connected Catheter Insertion
|
To evaluate successful removal of Connected Catheter
|
On the day of Connected Catheter Insertion
|
|
Successful Acute Performance- IV
Time Frame: On the day of Connected Catheter Insertion
|
To evaluate successful post-void sealing of Connected Catheter Valve
|
On the day of Connected Catheter Insertion
|
|
Successful Home-Use Performance
Time Frame: 29 days
|
Successful Home-Use using same measures as Acute Performance
|
29 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 28, 2018
Primary Completion (Actual)
June 30, 2018
Study Completion (Actual)
June 30, 2018
Study Registration Dates
First Submitted
January 9, 2018
First Submitted That Met QC Criteria
January 18, 2018
First Posted (Actual)
January 23, 2018
Study Record Updates
Last Update Posted (Actual)
September 26, 2018
Last Update Submitted That Met QC Criteria
September 24, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CoCath-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder, Neurogenic
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
APOGEPHA Arzneimittel GmbHCompletedUrologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor FunctionRomania, Austria, Germany
-
SanofiCompletedUrinary Bladder NeurogenicSerbia, United States
-
Ulrich MehnertNCCR (National Center of Competence in Resaerch, Switzerland)CompletedHealthy | Neurogenic Bladder Dysfunction Nos | Nonneurogenic Neurogenic Bladder DysfunctionSwitzerland
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionSwitzerland
-
Swiss Paraplegic Centre NottwilCompletedNeurogenic Bladder DysfunctionSwitzerland
-
The Methodist Hospital Research InstituteCollaborating for Advancement of Interdisciplinary Research in Benign UrologyCompletedOveractive Bladder | Lower Urinary Tract Symptoms | Neurogenic Bladder | Neurogenic Detrusor Overactivity | Neuro: Neurogenic BladderUnited States
-
Nemours Children's ClinicTerminatedDysfunctional Voiding | Neurogenic IncontinenceUnited States
-
Coloplast A/SCompletedNeurogenic Bladder Dysfunction NosDenmark, France, Germany, Norway, Sweden
-
SanofiCompletedNeurogenic Urinary BladderUnited States, France, Canada, Poland, Germany, Portugal, Spain, Turkey, Bulgaria, Estonia, India, Malaysia, Philippines, Russian Federation, Serbia, Singapore, Slovakia, Taiwan
Clinical Trials on Connected Catheter
-
Spinal SingularityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedUrologic Diseases | Urinary Retention | Neurogenic BladderUnited States
-
Spinal SingularityTerminatedUrinary Retention | ChronicUnited States
-
Spinal SingularityTerminatedUrologic Diseases | Urinary Retention | Neurogenic BladderUnited States
-
Medtronic BRCCompletedSleep ApneaNetherlands, Sweden
-
Ronald DeMatteo, M.D.Active, not recruitingIntrahepatic Cholangiocarcinoma | Colorectal Cancer Metastatic to LiverUnited States
-
ElsanActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
VA Office of Research and DevelopmentRecruiting
-
Gérond'ifRecruitingPatient Recovering Maximum Walking Capacity, Over 10 MeterFrance
-
Gérond'ifWithdrawnPatient Recovering Maximum Walking Capacity, Over 10 Meters